Paroxetine

Specifications

61869-08-7CAS Number

682-717-4EC Number

(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidineIUPAC Name

C19H20FNO3Chemical Formula

329.4 g/molMolecular Weight

paroxetine; 61869-08-7; Frosinor; Motivan; Casbol; PaxPar; Paroxetina; Paroxetinum; (-)-Paroxetine; Aropax; Besitram; BRL 29060; BRL-29060; Arketis; Daparox; Parogen; Xetanor; Arotin; FG-7051; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; FG 7051; (-)3s,4r-paroxetine; DTXSID3023425; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; CHEBI:7936; 41VRH5220H; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; DTXCID703425; (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-; (-)-TRANS-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE; (3S,4R)-3-((1,3-BENZODIOXOL-5-YLOXY)METHYL)-4-(4-FLUOROPHENYL)PIPERIDINE; (3S,4R)-3-((2H-1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-; PAXILCR; RefChem:6104; Paxil (as hydrochloride); N06AB05; BRL29060; FG7051; Paxil; Seroxat; Paroxetinum [INN-Latin]; Paroxetina [INN-Spanish]; Paxetil; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; (3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; (+/-)-Paroxetine; Paroxetine, (+/-)-; MFCD00869588; CHEMBL490; Paroxetine, trans-(+/-)-; 32Q7TW8BX7; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3S,4R)-; 130855-15-1; Paroxetine [USAN:INN:BAN]; CHEMBL1708; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3R,4S)-rel-; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, trans-; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, trans-(+/-)-; Rel-(3R,4S)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; CAS-61869-08-7; Paroxetine (USP/INN); UNII-41VRH5220H; 3h-paroxetine; Paroxetine.HCl; (3S,4R)-3-[(Benzo[d][1,3]dioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; NCGC00182968-01; 8PR; NNC-20-7051; Spectrum_001752; PAROXETINE [MI]; SpecPlus_000788; PAROXETINE [INN]; Prestwick3_000851; Spectrum5_001665; PAROXETINE [USAN]; PAROXETINE [VANDF]; PAROXETINE [MART.]; PAROXETINE [WHO-DD]; UNII-32Q7TW8BX7; Epitope ID:2278423; SCHEMBL27799; BSPBio_000861; KBioSS_002232; BIDD:GT0673; DivK1c_006884; BPBio1_000949; GTPL4790; orb1909599; orb3141301; SCHEMBL29358021; BDBM22416; HSDB 7175; KBio1_001828; KBio2_002232; KBio2_004800; KBio2_007368; HMS2090H05; Tox21_113123; BDBM50331515; EBC-26608; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; AKOS015888636; Tox21_113123_1; AC-8185; DB00715; SDCCGSBI-0051908.P003; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; NCGC00025355-02; NCGC00025355-03; NCGC00025355-04; NCGC00025355-05; NCGC00025355-06; NCGC00025355-07; NCGC00025355-08; NCGC00025355-09; NCGC00025355-12; NCGC00025355-13; NCGC00025355-22; NCGC00025355-23; SY289602; SBI-0051908.P002; HY-122272; AB00514724; CS-0083299; NS00000037; T8708; C07415; D02362; EN300-150199; AB00053704-21; AB00053704_22; AB00053704_23; F615527; paroxetine hydrochloride (anhydrous or hemihydrate); Q408471; BRD-K37991163-003-02-7; BRD-K37991163-003-13-4; BRD-K37991163-003-14-2; BRD-K37991163-050-05-1; BRD-K37991163-050-18-4; (3S,4R)-3-[(1,3-dioxaindan-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S,4R)-3-{[(2H-1,3-Benzodioxol-5-yl)oxy]methyl}-4-(4-fluorophenyl)piperidineSynonyms